

MATERIALS LICENSE

Amendment No. 07

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

301588

<p>Licensee</p> <p>1. Memorial Hospital of Burlington</p> <p>2. 252 McHenry Street Burlington, WI 53105-0257</p>	<p>In accordance with letter dated June 5, 1996</p> <p>3. License Number 48-18803-01 is amended in its entirety as follows:</p> <hr/> <p>4. Expiration Date November 30, 2000</p> <hr/> <p>5. Docket or Reference No. 030-14189</p>
--	---

6. Byproduct, Source, and/or Special Nuclear Material	7. Chemical and/or Physical Form	8. Maximum Amount that Licensee May Possess at Any One Time Under This License
<p>A. Any byproduct material identified in 10 CFR 35.100</p> <p>B. Any byproduct material identified in 10 CFR 35.200</p> <p>C. Any byproduct material identified in 10 CFR 35.300</p>	<p>A. Any radiopharmaceutical identified in 10 CFR 35.100</p> <p>B. Any radiopharmaceutical identified in 10 CFR 35.200 (excluding xenon-133)</p> <p>C. Any radiopharmaceutical identified in 10 CFR 35.300</p>	<p>A. As needed</p> <p>B. As needed</p> <p>C. As needed</p>

9. Authorized Use:

A. Medical use described in 10 CFR 35.100.

B. Medical use described in 10 CFR 35.200 (excluding xenon-133).

C. Medical use described in 10 CFR 35.300.

CONDITIONS

10. Location of Use: 301 Randolph Street, Burlington, WI 53103-0257.
11. Radiation Safety Officer: Gilbert S. Wadina, M.D.

9610280034 961017
PDR ADOCK 03014189
C PDR

COPY 4

MATERIALS LICENSE
SUPPLEMENTARY SHEETLicense Number
48-18803-01Docket or Reference Number
030-14189

Amendment No. 07

12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized UsersMaterial and Use

- | | |
|----------------------------|--|
| A. Lee H. Huberty, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133) and 35.300 (excluding iodine-131 for thyroid carcinoma). |
| B. Gregory Gullo, M.D. | 10 CFR 35.100 and 35.200 (excluding xenon-133). |
| C. Gilbert S. Wadina, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133) and 35.300 (excluding iodine-131 for thyroid carcinoma). |
| D. Kenneth E. Clark, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133) and 35.300 (excluding iodine-131 for thyroid carcinoma). |
| E. Lawrence J. Reif, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133) and 35.300 (excluding iodine-131 for thyroid carcinoma). |
| F. John Pallin, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133) and 35.300 (excluding iodine-131 for thyroid carcinoma). |
| G. Robert J. Swoboda, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133) and 35.300. |
| H. Donald J. Kash, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133) and 35.300 (excluding iodine-131 for thyroid carcinoma). |
| I. E. L. Koch, M.D. | 10 CFR 35.100 and 35.200 (excluding xenon-133). |
| J. Jane Cary Pallin, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133) and 35.300 (excluding thyroid carcinoma). |
| K. James Aceto, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133) and 35.300 (excluding thyroid carcinoma). |
| L. Mary Beth Barr, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133) and 35.300 (excluding thyroid carcinoma). |
13. The licensee shall follow the procedures in Appendix O of Reg. Guide 10.8 when using Tc-99m aerosols.

COPY

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

48-18803-01

Docket or Reference Number

030-14189

Amendment No. 07

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application received May 30, 1990; and
 - B. Letters dated May 18, 1994 (excluding authorization request for Dr. James Aceto and request for material in 10 CFR 35.300 (excluding thyroid carcinoma) for Dr. Carrie Pallin) and June 5, 1996.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date October 17, 1996

By

[Signature]
Nuclear Materials Licensing Branch, Region III

COPY

MATERIALS LICENSE

Amendment No. 07

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

301588

Licensee

1. Memorial Hospital of Burlington

2. 252 McHenry Street
Burlington, WI 53105In accordance with letter dated
June 5, 19963. License Number 48-18803-01 is amended
in its entirety as follows:

4. Expiration Date November 30, 2000

5. Docket or
Reference No. 030-141896. Byproduct, Source, and/or
Special Nuclear Material7. Chemical and/or Physical
Form8. Maximum Amount that Licensee
May Possess at Any One Time
Under This LicenseA. Any byproduct
material identified
in 10 CFR 35.100A. Any
radiopharmaceutical
identified in 10 CFR
35.100

A. As needed

B. Any byproduct
material identified
in 10 CFR 35.200B. Any
radiopharmaceutical
identified in 10 CFR
35.200 (excluding
xenon-133)

B. As needed

C. Any byproduct
material identified
in 10 CFR 35.300C. Any
radiopharmaceutical
identified in 10 CFR
35.300

C. As needed

9. Authorized Use:

A. Medical use described in 10 CFR 35.100.

B. Medical use described in 10 CFR 35.200 (excluding xenon-133).

C. Medical use described in 10 CFR 35.300.

CONDITIONS

10. Location of Use: 301 Randolph Street, Burlington, WI 53103-0257.

11. Radiation Safety Officer: Gilbert S. Wadina, M.D.

COPY

dl
2ml
230
SD

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number

48-18803-01

Docket or Reference Number

030-14189

Amendment No. 07

12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized UsersMaterial and Use

- | | |
|----------------------------|--|
| A. Lee H. Huberty, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133) and 35.300 (excluding iodine-131 for thyroid carcinoma). |
| B. Gregory Gullo, M.D. | 10 CFR 35.100 and 35.200 (excluding xenon-133). |
| C. Gilbert S. Wadina, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133) and 35.300 (excluding iodine-131 for thyroid carcinoma). |
| D. Kenneth E. Clark, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133) and 35.300 (excluding iodine-131 for thyroid carcinoma). |
| E. Lawrence J. Reif, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133) and 35.300 (excluding iodine-131 for thyroid carcinoma). |
| F. John Pallin, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133) and 35.300 (excluding iodine-131 for thyroid carcinoma). |
| G. Robert J. Swoboda, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133) and 35.300. |
| H. Donald J. Kash, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133) and 35.300 (excluding iodine-131 for thyroid carcinoma). |
| I. E. L. Koch, M.D. | 10 CFR 35.100 and 35.200 (excluding xenon-133). |
| J. Jane Cary Pallin, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133) and 35.300 (excluding thyroid carcinoma). |
| K. James Aceto, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133) and 35.300 (excluding thyroid carcinoma). |
| L. Mary Beth Barr, M.D. | 10 CFR 35.100, 35.200 (excluding xenon-133) and 35.300 (excluding thyroid carcinoma). |
13. The licensee shall follow the procedures in Appendix O of Reg. Guide 10.8 when using Tc-99m aerosols.

COPY

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
48-18803-01

Docket or Reference Number
030-14189

Amendment No. 07

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application received May 30, 1990; and
- B. Letters dated May 18, 1994 (excluding authorization request for Dr. James Aceto and request for material in 10 CFR 35.300 (excluding thyroid carcinoma) for Dr. Carrie Pallin) and June 5, 1996.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date October 17, 1996

By


Nuclear Materials Licensing Branch, Region III

COPY

BETWEEN:

(FOR LFMS USE)
INFORMATION FROM LTS

LICENSE FEE MANAGEMENT BRANCH, ARM
AND
REGIONAL LICENSING SECTIONS

PROGRAM CODE: 02120
STATUS CODE: 0
FEE CATEGORY: 7C
EXP. DATE: 20001130
FEE COMMENTS:
DECOM FIN ASSUR RECDT N

55

LICENSE FEE TRANSMITTAL

A. REGION

1. APPLICATION ATTACHED
APPLICANT/LICENSEE: MEMORIAL HOSPITAL OF BURLINGTON
RECEIVED DATE: 960712
DOCKET NO: 3014189
CONTROL NO.: 301588
LICENSE NO.: 48-18803-01
ACTION TYPE: AMENDMENT

2. FEE ATTACHED
AMOUNT: 0
CHECK NO.: 0

3. COMMENTS

SIGNED
DATE

D. Hersey
7-16-96

B. LICENSE FEE MANAGEMENT BRANCH (CHECK WHEN MILESTONE 03 IS ENTERED / 11)

1. FEE CATEGORY AND AMOUNT: 7C \$440

2. CORRECT FEE PAID. APPLICATION MAY BE PROCESSED FOR:
AMENDMENT
RENEWAL
LICENSE

3. OTHER

SIGNED
DATE

SC 8/14/96

1996 JUL 22 PM 1:47

RECEIVED
AUG 19 1996
REGION III

Log	Jul 11 III
Remitter	
Check No.	69813 75747
Amount	\$430
Fee Category	7C
Type of Fee	Amnd
Date Check Rec'd	7/23/96
Date Completed	8/14/96
By:	SC

MEMORIAL HOSPITAL OF BURLINGTON
252 Mc Henry Street
Burlington, WI 53105-0257

June 5, 1996

U. S. Nuclear Regulatory Commission
Region III
Licensing Section
801 Warrenville Road
Lisle, Illinois 60532-4351

RE: Amendment to Radioactive Materials License #48-18803-01

Dear Sir or Madam:

Please amend the above referenced radioactive materials license to reflect the following:

1. Please change the name of our hospital from "Memorial Hospital" to "Memorial Hospital of Burlington". This name change resulted from an affiliation with Aurora Health Care Systems. This is not a change of ownership and no changes in management. This is only a name change.
2. Please add the following authorized users to our radioactive materials license:
 - a. Mary Beth Barr, M. D. - Materials identified in 10CFR35.100 and 10CFR35.200 (excluding Xenon-133).

Please reference attached board certification.

- b. Gregory Gullo, M.D. - Materials identified in 10CFR35.100 and 10CFR35.200 (excluding Xenon-133).

Please reference attached board certification.

- c. Jane Cary Swanson Pallin, M.D. - Materials identified in 10CFR35.100 and 10CFR35.200 (excluding Xenon-133).

Please reference attached board certification and radioactive materials license #48-01670-01.

RECEIVED

JUL 12 1996

REGION III

AUG 19 1996

03014189
301588

- d. James Aceto, M. D. - Materials identified in 10CFR35.100 and 10CFR35.200 (excluding Xenon-133).

Please reference attached board certification.

- e. Theodore A. Keller, M. D. - Materials identified in 10CFR35.100 and 10CFR35.200 (excluding Xenon-133).


Please reference attached board certification and radioactive materials license #48-01670-01.

3. Please delete Gene F. Armstrong, M. D. from our facility's license. He is no longer working at our facility as an authorized user.

Enclosed is a check for \$430.00 to cover the fees to process this amendment.

We hope this information is sufficient to grant our amendment requests. If you have any questions regarding this amendment, please contact Sue Harris at (414) 763-0369.

Sincerely,

A handwritten signature in cursive script, appearing to read "Paul A. Miller".

Paul Miller
Chief Executive Officer

QUALITY MEANS MEETING THE REQUIREMENTS BOX 4514
SEQ# 006 \$ 0000430000 BA# 13 07-01-96 15 5

MEMORIAL HOSPITAL CORPORATION OF BURLINGTON
BURLINGTON, WI 53105

U.S. NUCLE 3069 6/28/96 CHECK NO 69814

Am0422-96

NO 069814

VOID UNLESS PRESENTED FOR PAYMENT IN 90 DAYS

PAY FOUR THOUSAND THREE HUNDRED DOLLARS AND NO CENTS

BANK ONE ELKHORN NA
BURLINGTON OFFICE
BURLINGTON, WISCONSIN

TO THE
ORDER OF

U.S. NUCLEAR REGISTRY COMM
PO BOX 954514
ST LOUIS

MO 63195-4514

\$4,300.00

[Signature]

AUTHORIZED SIGNATURE

⑆069814⑆ ⑆075903⑆29⑆ ⑆9200⑆0249⑆


⑆0000430000⑆

MEMORIAL HOSPITAL CORPORATION OF BURLINGTON
BURLINGTON, WI 53105

U.S. NUCLE 3069 6/28/96 CHECK NO 69814

INVOICE DATE	INVOICE NUMBER	DESCRIPTION	P.O. NUMBER	GROSS AMOUNT	DISCOUNT AMOUNT	NET AMOUNT
62096	AM0422-96		100	4,300.00		4,300.00
<i>For Annual Fee Only - Not for amendment.</i>						
TOTALS ▶				4,300.00		4,300.00

REMITTANCE ADVICE DEPOSIT AFTER DETACHING



LICENSE FEE REQUIREMENTS

COPY
LICENSE FEE AND DEBT COLLECTION BRANCH
DIVISION OF ACCOUNTING AND FINANCE
OFFICE OF THE CONTROLLER
U.S. NUCLEAR REGULATORY COMMISSION
WASHINGTON, DC 20566-0001MEMORIAL HOSPITAL OF BURLINGTON
ATTN: PAUL MILLER
CHIEF EXECUTIVE OFFICER
252 McHENRY STREET
BURLINGTON, WISCONSIN 53105-0257

TYPE OF ACTION

- ☐
- NEW LICENSE
-
- ☐
- RENEWAL OF LICENSE
-
- ☒
- AMENDMENT TO LICENSE

REQUESTED DATE

6-5-96

LICENSE NUMBER

48-18803-01

CONTROL NUMBER

301588

I. APPLICATION FEE DUE

Your request for a licensing action is subject to the fee(s) in the category(ies) noted below in accordance with Section 170.31 of the enclosed Federal Register notice. Payment of the fee is required prior to the issuance of the license, renewal, or amendment.

FEE CATEGORY	APPLICATION	RENEWAL	AMENDMENT
7C	\$	\$	\$ 440.00
	\$	\$	\$
	\$	\$	\$
	\$	\$	\$
	\$	\$	\$
	\$	\$	\$
	\$	\$	\$
	\$	\$	\$
	\$	\$	\$
	\$	\$	\$

FEE(s) DUE	\$	440.00
PAYMENT RECEIVED	\$	430.00
AMOUNT DUE	\$	10.00

☐ Your request was received without the prescribed application fee.☒ We received your Check No. 69813 in the amount of \$ 430.00. Payment of the additional fee noted above is required.☐ Your request will increase the scope of your license program. Therefore, your request is subject to the application fee(s) noted above. Refer to Section 170.31 and Footnote 1(d)(2).☐ Your license expired prior to the receipt of your application for renewal. Therefore, your request is subject to the application fee(s) noted above. Refer to Section 170.31 and Footnote 1(a).

MAKE PAYMENT OF THE FEE(S) TO THE U.S. NUCLEAR REGULATORY COMMISSION AND MAIL THE PAYMENT TO THE ADDRESS LISTED AT THE TOP OF THIS FORM. IF WE DO NOT RECEIVE A REPLY FROM YOU WITHIN 30 CALENDAR DAYS FROM THE DATE LISTED BELOW, WE SHALL ASSUME THAT YOU DO NOT WISH TO PURSUE YOUR APPLICATION AND WILL VOID THIS ACTION.

SIGNATURE - LICENSE FEE ANALYST

LFDCB

LFDCB

SHIRLEY SCRATCHFIELD

7/25/96

II. FEE NOT REQUIRED

☐ Enclosed is Check No. _____ which accompanied your request. The fee is not required because:☐ We received your Check No. _____ in payment of the fee.☐ The Licensing staff has informed us that your request is to be considered as a continuation of your request dated _____, Control No. _____.☐ Your request was combined, prior to review, with your _____ request, Control No. _____.

III. CHECK RETURNED

☐ Enclosed is Check No. _____ which was returned to us by the bank for:☐ INSUFFICIENT FUNDS☐ ACCOUNT CLOSED☐ OTHER

MAIL THE REPLACEMENT CHECK TO THE ADDRESS LISTED AT THE TOP OF THIS FORM AND REFERENCE THE ABOVE CONTROL NUMBER.

IV. LICENSE ISSUED WITHOUT THE REQUIRED FEE

☐ License No. _____, Amendment No. _____, issued on _____ was issued without the required fee being collected. The fee required is noted in Section I of this form.☐ The scope of your licensed program was increased. Therefore, your request is subject to the application fee(s) noted in Section I of this form. Refer to Section 170.31 and Footnote 1(d)(2).☐ Because of the urgency of your request, the license was issued without remittance of the prescribed fee noted in Section I of this form.

Distribution:

Pending Fee File OC/DAF/RF
LFARB R/F (2) Region 3

DATE

July 25, 1996

The American Board of Radiology

Organized through the cooperation of the
American College of Radiology, the American Roentgen Ray Society,
the American Radium Society, the Radiological Society of North America,
the Section on Radiology of the American Medical Association,
the American Society for Therapeutic Radiology and Oncology, the Association of
University Radiologists, and American Association of Physicians in Medicine
Hereby certifies that

Gregory J. Gullu


Has pursued an accepted course of graduate study
and clinical work, has met certain standards and qualifications and
has passed the examinations conducted under the authority of

The American Board of Radiology

On this ninth day of June, 1994

Thereby demonstrating to the satisfaction of the Board
that he is qualified to practice the specialty of

Diagnostic Radiology



Lee F. Rogers, M.D., President



OCT 18 1996

Paul Miller, CEO
Memorial Hospital of Burlington
252 McHenry Street
Burlington, WI 53105-0257

Dear Mr. Miller:

Enclosed is Amendment No. 07 to your NRC Material License No. 48-18803-01 in accordance with your request.

Please review the enclosed document carefully and be sure that you understand all conditions. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region III office at (630) 829-9887 so that we can provide appropriate corrections and answers.

Please be advised that your license expires at the end of the day, in the month, and year stated in the license. Unless your license has been terminated, you must conduct your program involving byproduct materials in accordance with the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate in accordance with NRC regulations 10 CFR Part 19, "Notices, Instructions and Reports to Workers; Inspections," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.
2. Notify NRC, in writing, within 30 days:
 - a. When an authorized user or Radiation Safety Officer permanently discontinues performance of duties under the license or has a name change; or
 - b. When the licensee's mailing address changes (no fee is required if the location of byproduct material remains the same).
3. In accordance with 10 CFR 30.36(b) and/or license condition, notify NRC, promptly, in writing, and request termination of the license when you decide to terminate all activities involving materials authorized under the license.

301588

4. Request and obtain a license amendment before you:
 - a. Receive or use byproduct material for a clinical procedure permitted under Part 35 but not permitted by your license issued pursuant to this Part;
 - b. Permit anyone, except individuals described in 10 CFR 35.13(b), to work as an authorized user under the license;
 - c. Change Radiation Safety Officers;
 - d. Order byproduct material in excess of the amount, or radionuclide, or form different than authorized on the license;
 - e. Add or change the areas of use or address or addresses of use identified in the license application or on the license; or
 - f. Change ownership of your organization.
5. Submit a complete renewal application with proper fee or termination request at least 30 days before the expiration date of your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of byproduct material after your license expires is a violation of NRC regulations. A license will not normally be renewed, except on a case-by-case basis, in instances where licensed material has never been possessed or used.

In addition, please note that NRC Form 313 requires the applicant, by his/her signature, to verify that the applicant understands that all statements contained in the application are true and correct to the best of the applicant's knowledge. The signatory for the application should be the licensee or certifying official rather than a consultant.

You will be periodically inspected by NRC. Failure to conduct your program in accordance with NRC regulations, license conditions, and representations made in your license application and supplemental correspondence with NRC will result in enforcement action against you. This could include issuance of a notice of violation, or imposition of a civil penalty, or an order suspending, modifying or revoking your license as specified in the General Policy and Procedures for NRC Enforcement Actions. Since serious consequences to employees and the public can result from failure to comply with NRC requirements, prompt and vigorous enforcement action will be taken when

P. Miller

-3-

dealing with licensees who do not achieve the necessary meticulous attention to detail and the high standard of compliance which NRC expects of its licensees.

Sincerely,

Original Signed By
Gidget Watson
Nuclear Materials Licensing Branch

License No.: 48-18803-01
Docket No.: 030-14189

Enclosure: Amendment No. 07

DOCUMENT NAME: M:\03014189.CL6

To receive a copy of this document, indicate in the box: "C" = Copy without attachment/enclosure "E" = Copy with attachment/enclosure "N" = No copy

OFFICE	DNMS/RIII								
NAME	GWATSON:jaw								
DATE	07/1796 <i>HW</i>								

10

OFFICIAL RECORD COPY



UNITED STATES
NUCLEAR REGULATORY COMMISSION

REGION III
801 WARRENVILLE ROAD
LISLE, ILLINOIS 60532-4351

July 19, 1996

Gilbert S. Wadina, M.D.
Radiation Safety Officer
Memorial Hospital of Burlington
252 McHenry Street
Burlington, WI 53105

SUBJECT: ACKNOWLEDGEMENT OF CORRESPONDENCE
(☒ Letter ☐ Application ☐ Dated June 5, 1996)

Dear Licensee:

In response to your request, we have completed the initial processing, which is an administrative review of your application for a(n):

☐ New License ☒ Amendment ☐ Renewal
☐ Termination ☐ Auth User (Amendment not required) ☐ QMP Revision
☐ Other _____

Administrative deficiencies were identified during this initial review as outlined below. However, it should be noted that a technical review may identify additional omissions in the submitted information, technical issues that require additional information, or policy/technical issues that require coordination with headquarters or other NRC regional offices.

It appears that your request is routine (see 1-3 below as, applicable); however, your request is incomplete.

Incomplete information is as follows: In order for us to complete your request the required fee is necessary. Please contact our License Fee & Debt Collection Branch, located in our headquarters office, as referenced below. Your letter states that you have enclosed a \$430. fee which was not in the package. We do have your xerox copy of your check for your annual fee, and it is marked for "annual fee only."

1. New and amendment actions are normally processed within 90 days, unless we find major deficiencies, or policy issues requiring central program office assistance.
2. Renewal actions are normally processed within 180 days, however under timely filing (before expiration) you may continue to operate under your existing license.
3. Termination actions are normally processed within 90 days, unless confirmatory surveys following decontamination/decommissioning activities are involved.

A copy of your correspondence has been forwarded to our Licensing Fee and Debt Collection Branch (301/415-6097) for approval of the fee category and amount.

If you have a compelling safety or business-related reason for requesting expedited review, please contact the Materials Licensing Branch at (708) 829-9887. We will try to complete your request as soon as practicable. Any correspondence about this request should reference the control number.

Nuclear Materials Support Branch